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Background: The vulva is an unusual site for basal cell carcinoma (BCC). Vulvar BCC accounts 
for less than 1% of all BCCs, and less than 5% of all vulvar malignancies.  We report the case of 
an 83 year-old woman who presented with a two-month history of a tender labial growth, with 
histopathology confirming nodular BCC. We conducted a systematic literature review of the 
characteristics of reported cases of vulvar BCCs. 
 A comprehensive systematic review of articles indexed for MEDLINE and Embase 
yielded 96 reports describing 437 patients with 446 BCCs of the vulva. 
 The mean age at presentation was 70 (range 20 to 100). Most women had no underlying 
vulvar disease. Approximately 60% of cases were of the nodular subtype. Treatment approach 
varied widely with over half of cases treated with wide local or local excision. Mohs 
micrographic surgery (MMS) for vulvar BCC was first reported in 1988 with seven total MMS 
cases reported.  Twenty-three cases of recurrence have been reported; 21 of these cases after 
local excision, but none following MMS.  
 Vulvar BCC is rarely reported cancer that affects older women predominantly. 
MMS represents a promising treatment for BCC in this anatomic location. 
 
 
 
 
While basal cell carcinomas (BCC) are the most common human malignancy, the vulva 
is an unusual location with vulvar BCCs accounting for less than 1% of all BCCs.1 Additionally, 
BCC of the vulva accounts for less than 5% of all vulvar malignancies.2,3 BCC of the vulva most 
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commonly affects elderly women. Presenting symptoms include pruritus, a lump, bleeding, and 
pain.4 The proposed risk factors for BCC occurring in non sun-exposed sites such as the vulva 
include radiation therapy and basal cell nevus syndrome.5,6
 
 Treatment options for vulvar BCCs 
include radical and simple vulvectomy, wide local excision, simple surgical (local) excision and 
Mohs micrographic surgery (MMS). We report the case of an 83 year-old woman who presented 
with a BCC of the vulva. We also review the characteristics of the reported cases of vulvar BCCs 
in the literature, including treatment approach.   
 Repor t 
An 83 year-old woman with a 40-year history of treated lichen sclerosus presented with a 
tender growth in the genital area for two months. Genital examination revealed a 5mm eroded 
papule on the right inferolateral labium majus arising on normal skin, and a white, sclerotic 
appearance of the labia minora and clitoris (Figure 1). Biopsy of the papule revealed a nodular 
BCC. The patient underwent MMS. She has no evidence of disease recurrence at 3 years.  
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A comprehensive systematic review of articles indexed for MEDLINE and Embase using 
the terms basal cell carcinoma or basal cell cancer or basal cell epithelioma or basal cell tumor 
or basal cell tumour or BCC and vulva or vulvar or vulval was performed.  Rule-in criteria 
included anatomic localization of BCCs to the external female genitalia, English language 
abstract and article text, and non-duplication of cases.  Exclusion criteria included lesions not 
confirmed as BCC by biopsy, ambiguous language regarding anatomic location, as well as 
review articles or opinion pieces that do not characterize a specific patient case.  Two 
independent reviewers screened titles and abstracts for relevance. Two reviewers assessed the 
remaining articles for inclusion, with disagreements going to a third reviewer. Only 
published case reports or case series in peer-reviewed journals were included in this review, with 
publication years ranging from 1950 to 2015.  Case series that presented case reports in 
aggregate form were included even if these reports did not specify lesion details beyond location 
and histopathology. In most case reports, lesion size, specific anatomic site, patient age, 
treatment, recurrence, associated metastases, and provider specialty were available.  These data 
were noted and tabulated yielding 96 reports in the English literature describing 437 patients 
with BCCs of the vulva.1-96  
 
Of the 96 reports, 41 were published in the gynecology or 
gynecologic oncology literature, 29 in the dermatology literature, and 26 in non-gynecology, 
non-dermatology literature (pathology, surgery, oncology, medicine).  
The mean age at presentation was 70 years (range 20 to 100). Of the 437 patients, 7 
patients had more than one vulvar tumor ( 2 of whom had 3 primary tumors) resulting in a total 
of 446 cases of vulvar BCC.5,6,32,38,53,54 Risk factors for the 7 patients with multiple BCC of the 
vulva included 4 patients with a previous history of multiple BCC on sun-exposed sites32,38,53,54, 
2 patients with history of radiation to pelvis5,54, and 3 patients with Gorlin’s syndrome.6,14 
Overall, most women did not have underlying vulvar disease; however, in 3 patients, BCCs arose 
in contiguity with extramammary Paget disease.7,44,63 Two BCCs arose within an area of lichen 
sclerosus57,88 while in a third case, a BCC arose adjacent to the area affected by lichen 
sclerosus34
Anatomic site 
, as was seen in our patient. 
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The exact site on the vulva was documented in 212 cases. The labium majus was the site 
of origin in 162 cases, the clitoris in 10, labium minus in 8, perineum in 4, vagina/surrounding 
introitus and posterior fourchette in 3 each, and one BCC arose from the periurethral mucosa. 
Twenty-one further cases involved more than one anatomic location due to the larger size of 
tumor at presentation. Potential risk factors in these patients include underlying extramammary 
Paget disease in two women7,44, five patients with aggressive histology such as infiltrative, 
morpheaform and infundibulocystic BCC patterns7,56,61,71,92, two patients with a history of 
previous BCC on sun-exposed sites71,76, and seven patients with a documented late presentation,  
with either lesion ulceration, large size, and/or metastases.36,60,61,62,71,92
Histopathologic subtype 
  
Specific histopathologic subtype of the BCC was documented in 199 cases (Figure 2) and 
included 116 (58%) cases that were nodular, 30 (15%) superficial and 27 (14%) infiltrative. 
There were 10 documented cases displaying more than one BCC histopathologic subtype—6 
were nodular, infiltrative, and superficial; 3 were nodular and superficial; 1 was nodular and 
infiltrative and contiguous with a squamous cell carcinoma (SCC). Other reported 
histopathologic diagnoses were 4 cases of mixed BCC and SCC, 3 total cases of BCC contiguous 
to SCC (one mentioned above), and 10 cases of basosquamous cell carcinoma (BSC). Of the 10 
cases of BSC, one case of BSC was infiltrative and metastatic to bone. This patient also had a 
history of basal cell nevus syndrome.14
Therapeutic approach 
  
Surgical treatment approaches varied widely and were documented in 353 cases. The 
most common surgical treatment was wide local excision in 88 (25%) cases and simple surgical 
(local) excision in 173 (49%). Vulvectomy was also reported with 40 (11%) cases of bilateral 
simple vulvectomy, 23 (7%) cases of radical vulvectomy of which 17 had concomitant lymph 
node dissection, and 9 (3%) cases of hemi- or partial vulvectomy of which 2 cases had 
concomitant lymph node dissection. The indication for lymph node dissection in these 19 
patients included 7 patients with palpable inguinal lymphadenopathy and 3 patients because 
biopsy revealed BSC histology.15,53,56 Other reasons for lymph node dissection included 3 cases 
with initial diagnosis of SCC or adenocystic carcinoma15,55 and 1 case due to large tumor size 
and concern for involvement of the clitoral lymphatic network.23 Indications for lymph node 
dissection were not specified in the remaining 5 cases. Eight cases were treated with excisional 
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biopsy alone, 4 cases were treated with radiation therapy, and 3 cases were treated with 
electrocautery.  
Seven (2%) total cases of MMS for the treatment of vulvar BCC have been reported.  The 
first reported cases of vulvar BCC treated with MMS were in 1988 when 2 patients with BCC 
located on the perineum were successfully treated with MMS.20 An additional 5 cases of vulvar 
BCC have since reported treatment with MMS.2,65,76 A study by Gibson et al. found 8 cases of 
perianal and genital BCC successfully treated with MMS; however, this report does not specify 
whether these BCC were located on the vulva.1
Local recurrence  
 Our case documents an additional vulvar BCC 
successfully treated with MMS.  
Twenty-three cases of local recurrence have been documented in the literature (5.1% of 
446 cases) (Table I). Twenty-one of these cases occurred following local excision (7 completely 
excised, 7 incompletely excised, 6 unspecified). The remaining cases recurred after radical 
vulvectomy and lymphadenectomy, x-ray therapy followed by direct radium application, and 
excisional biopsy with tumor-free margins. Of the 14 recurrent cases in which age was reported, 
patients were an average of 69 years old (range 44 to 92). The histopathological characteristics of 
primary BCC lesions that recurred were specified in 10 cases.10,34,61,69,77,95 There was notable 
variation, including cases with both low34 and high34,77 mitotic counts.  Squamous change was 
evident in 5 primary tumors.
Recurrent lesions were most often treated with local excision. Four patients died from 
recurrent disease—one from local tumor invasion leading to hemorrhage and septicemia, another 
from local spread and infection, a third from renal failure due to pelvic and abdominal disease, 
and a fourth from respiratory distress secondary to lung metastases.
34,61,69,95
 
15,34,80,95
 Multiple recurrences 
were not uncommon, occurring in four BCC cases. Of the cases involving a single recurrence, 
time to recurrence ranged from 6 months to 13 years. Three series of BCC cases revealed a local 
recurrence rate of 8.9-10.7%.15,34,82
Metastatic BCC 
 No recurrence after MMS has been reported (Table III). 
Twelve cases in this series of 446 were metastatic (2.7%). Table II presents key features 
of these cases. Of the 11 metastatic cases in which age was reported, patients were an average of 
74 years old (range 41 to 87). BCC was metastatic to inguinal lymph nodes in 9 of the 12 cases. 
Palpable lymphadenopathy on the side of histologically confirmed metastases was appreciated in 
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only 3 of these cases. There was 1 reported case of distant nodal metastasis (supraclavicular 
lymph node)15 and 4 cases of hematogenous spread  (right thigh skin, pubic bone, femoral head, 
lung).61,62,77,95 Metastatic BCC lesions tended to be large and deeply infiltrative. The depth of 
involvement was reported in 4 cases,34,62,71,86 with the deepest penetration measuring 6 cm.62
Perrone et al. compared their single case of metastatic BCC to 10 cases of nonmetastatic 
BCC. They found that the metastatic lesion was distinguished by extensive local involvement of 
the urethra and vagina, clinical history of vaginal bleeding secondary to tumor infiltration, deep 
penetration into subcutaneous fat, and a morphea-like growth pattern.
 In 7 
cases, the primary BCC invaded subcutaneous tissue or fat, and in 2 cases the tumor extended to 
the pubic bone.  
71
 Two cases of metastatic 
BCC were notable for delayed presentation—one patient noticed “something growing” on her 
vulva for approximately 5 years before seeking treatment, and another patient presented with a 
14-year history of a lump on the mons pubis.86,92
Most patients with metastatic disease were treated with radical vulvectomy and bilateral 
inguinal lymphadenectomy. The patient with femoral head metastasis did not undergo inguinal 
node dissection because of known hematogenous spread and a primary goal of palliation.
  
62
 
Radiation therapy was performed on 5 patients. Winkelmann et al. present a case of a large and 
locally invasive tumor that rendered the patient an inoperable candidate. This patient was treated 
with pre-operative radiation that resulted in complete resolution of the tumor prior to radical 
vulvectomy and proctectomy with inguinal lymphadenectomy.92 Four patients with metastatic 
BCC died from the disease.
 
15,34,62,95
 
Although BCC is a common malignancy, the vulva is an unusual anatomic location for 
BCC and accounts for less than 1% of all BCC. We reviewed over 400 published cases of vulvar 
BCC in the literature and found that vulvar BCCs most often affect postmenopausal females over 
the age of 70. The most common location is the labium majus. Vulvar BCC is rarely associated 
with underlying vulvar disease such as extramammary Paget disease or lichen sclerosus.  
Vulvar BCC is histopathologically similar to BCC occurring in other anatomic 
locations.19 Certain histologic types such as basosquamous carcinoma, adenocystic and 
infiltrative types tend to be more aggressive and may explain cases of recurrence.97 Lymph node 
involvement and hematogenous metastasis to distant sites are rare but can occur. Treatment 
Au
th
or
 M
an
us
cr
ip
t
8 
This article is protected by copyright. All rights reserved 
approaches varied widely in reported literature. Most cases were treated with wide local 
excision. A minority of patients underwent simple or radical vulvectomy. Seven cases treated 
with MMS have been well documented in the literature.   
In our review of 437 patients with vulvar BCC, 23 (5.1%) recurred and 12 (2.7%) 
metastasized. Studies estimate a recurrence rate of 4.2% (follow up < 5 yrs) and 8.7% (follow up 
> 5yrs) for all BCCs 98 and the reported incidence of metastatic BCC for all BCCs ranges from 
0.0028%-0.55%.5, 65 These vulvar recurrence and metastatic rates are likely underestimated, as 
patient follow-up was limited in most case reports. Because of the low incidence of vulvar BCC, 
it remains difficult to define factors associated with increased risk of recurrent or metastatic 
disease. Several reported cases of local recurrence followed incomplete excision, though the 
presence or absence or positive surgical margins does not appear predictive of recurrence. High 
recurrence rates have been reported in the literature with local recurrence after complete local 
excision in about 10-20% of cases, possibly due to inadequate surgical margins.69
MMS has been associated with improved cosmetic and functional outcomes.
 Advanced 
vulvar BCC often involves metastasis to inguinal lymph nodes, though distant nodal metastasis 
and hematogenous spread are also possible. Based on our review, potential risk factors for 
metastatic disease include large size (including from late presentation), depth of involvement, 
and aggressive histologic features. Though uncommon, both recurrent and metastatic BCC can 
be fatal. 
5,65
 MMS 
may be the best chance of cure, especially with increased tumor size, aggressive histology, and 
when maximum uninvolved tissue preservation is desired.20
Questions (answers found after references) 
 The use of MMS for treatment of 
vulvar BCC may lead to improved rates of local recurrence.   MMS represents a promising 
treatment for BCC in this anatomic location, however further experience with MMS for vulvar 
BCC is needed to confirm this observation 
 
1. In which decade do most patients experience vulvar BCC?  
a) Fifth 
b) Sixth 
c) Seventh 
d) Eighth 
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2. Which of the following is not a potential risk factors for BCCs developing in non sun-exposed 
areas?   
a) Radiation therapy 
b) Basal cell nevus syndrome 
c) Recurrent infection 
d) Lichen sclerosus 
 
3. The majority of the articles reviewed in this manuscript come from which literature sources?  
a) Gynecology 
b) Gynecological oncology 
c) Dermatology  
D) Surgical oncology  
4. What is the most common site for vulvar BCCs?  
a) Introitus 
b) Posterior fourchette 
c) Periurethral 
d) Labium majus 
5. What is the most common histological subtype of vulvar BCC?   
a) Superficial 
b) Nodular  
c) Infiltrative 
d) Basosquamous 
6. What is the recurrence rate of vulvar BCCs?   
a) 1.4% 
b) 3.5% 
c) 5.1% 
d) 8.5% 
7. After which treatment modality did most vulvar BCC recurrences occur?  
a) Mohs micrographic surgery 
b) Electrodessication and curettage 
c) Local excision 
 
8. What percentage of vulvar BCCs result in metastasis?  
a) 1.5% 
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b) 2.7% 
c) 5.1% 
d) 7% 
9. What is the most common location for vulvar BCC metastasis? 
a) Inguinal lymph node 
b) Retroperitoneal lymph node 
c) Distant site 
d) Uterus 
10. In the author’s opinion, what is the preferred method for vulvar BCC treatment? 
a) Local excision 
b) Electrodessication & curettage 
c) Mohs micrographic surgery 
 
 
 
Figure legends
 
. 
Figure 1. BCC arising from the labium majus. Changes of treated lichen sclerosus also seen. 
 
 
Figure 2. Histopathologic subtypes of vulvar BCCs (n=199) 
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Figure 2 
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Table I: BCC Recurrences 
 
Article 
Recur rence 
  
No Notable 
Patient 
History 
  
Size  , 
Extent 
 Treatment Recurrence Recurrence Treatment/ Outcome 
 
 
r ecur renc
e 
Features 
Siegler  et  
 
1 Age 49 Size: 3 X-ray therapy, followed 
by radium applied directly 
to the lesion 
12 Local recurrence Radical vulvectomy with removal of 
posterior and lateral vaginal walls, post-
operative radiation. Pt died one year later 
of local spread and infection. 
Abell et  
 
2 Age 44 Size: 2.5 Local excision (complete) ~156 Local recurrence Vulvectomy and bilateral inguinal lymph 
node dissection. 
Palladino et  
 
3 Age 39 --- Local excision 24 then 72 Local recurrence Local re-excision both times. Pt died of 
squamous cell CA of lung 11 yrs after 
biopsy of primary BCC lesion. 
4 Age 69 Size: 1.5 Local excision 36 Local recurrence Local re-excision. Disease-free 6 years 
following original excision. 
 et 
al.,  
5 Age 53 --- Local excision 13 then 22 Local recurrence 
 
* At the time of 3rd
Chemotherapy followed by local radiation. 
Pt’s lungs deteriorated and she died of 
respiratory failure due to lung metastases.    
recurrence, pt was 
diagnosed with metastatic 
BCC 
Deppisch et  
 
6 Age 56 --- Local excision 6 Local recurrence Local re-excision. Disease-free at 5-year 
follow-up 
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Zerner  et  
 
7 Age 87 --- Local excision (complete) --- Local recurrence --- 
8 Age 92 Size 3 x 5 Local excision (complete) --- Local recurrence --- 
Simonsen et  
 
 
9.5%  (2/21) 
9-10 --- --- Local excision (complete) ~60 Local recurrence Local surgical extirpation 
 et  
 
11 Age 87  
Renal cell 
CA 
--- Local excision 60 Local recurrence (3x5cm) Local re-excision (complete). Pt died one 
month later of MI 
12 Age 89 
2 BCC 
recurrence
s 
--- Local excision (complete) 120 
*time to 
3rd
Local recurrence (3 
lesions, largest 4x7mm) 
 
recurrence 
Local re-excision (complete). Disease-free 
at 6 month follow-up. 
Feakins et  
 
 
8.9% (4/45) 
13 --- Size: >5, nodal 
metastases 
Radical vulvectomy, 
inguinal 
lymphadenectomy 
(complete) 
23 Local recurrence Tumor eroded into inguinofemoral blood 
vessels causing hemorrhage and 
septicemia. Patient died from BCC. 
14-16 --- --- Local excision 
(incomplete) 
--- Local recurrence --- 
Benedet et  
 
 
10.7% (3/28) 
17-18 --- --- Wide local excision 
(incomplete) 
24 --- Local re-excision (complete)  
19 Age 80 Size 2 x 1 Wide local excision 
(incomplete), followed by 
immediate re-excision 
(complete) 
72 Local recurrence 
 
*After primary treatment, 
prior to local recurrence, 
pt presented with 
metastatic BCC in 
supraclavicular node  
Irradiated supraclavicular nodal metastasis 
(apparently complete resolution). Pt died 
of renal failure 2 years later, due to pelvic 
and abdominal disease. Au
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Piura et  
 
20 Age 62 Size: 2 Wide local excision 
(complete) 
65 Local recurrence Local excision (complete). Disease-free at 
15 month follow-up.  
21 Age 72 
Breast CA 
Size: 1 Excisional biopsy with 
tumor free margins 
(required repeat excisional 
biopsy at 6 months due to 
first recurrence) 
16  
*time to 
2nd
Local recurrence 
 
recurrence 
Right hemivulvectomy (complete). 
Disease-free at 143 month follow-up. 
Gibson et  
 
22 --- --- Wide excision 84 --- --- 
 et  
 
23 Age 87 Size: 5 x 3.7 Local excision (complete) 55  Presented with ulcerated, 
indurated left inguinal 
lesion. CT showed 25mm 
x 22mm mass in left 
inguinal region ( 
recurrence vs. lymph node 
metastasis) MRI showed 
metastasis to pubic bone  
Surgical excision, then palliative 
treatment. Pt alive and well at 14 month 
follow-up 
 
 
 
 
 
 
 
 
Table II: BCC metastases 
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Article No Age  Palpable 
 
 
Site  Metastasis Treatment/Outcome 
 
Size   Histologic Features 
 
et   
1 53 --- Mixed solid and 
adenoid type 
No Lung Chemotherapy followed by local radiation. Pt’s 
lungs deteriorated and she died of respiratory 
failure due to lung metastases. 
J imenez et 
  
2 41 5 x 5 x 2.5 
 
Infiltrated deep and 
lateral subcutaneous 
tissues 
Infiltrative, small foci 
of squamoid cells 
Yes (left)  Inguinal lymph nodes 
(left, both superficial 
and deep) 
Radical vulvectomy, bilateral lymph node 
dissection 
 et 
  
3 71 8 x 4.5 
 
Extended 0.5 cm into 
adjacent fat. 
Solid and adenoid, 
many mitotic figures 
No Lymph nodes in 
subcutaneous fat (5 
total) 
Lesion completely excised 
  
  
4 86 “Large” 
 
Infiltrated lateral wall of 
vagina, urethra, 
subcutaneous fat 
(thickness=1.2) 
Adenoid, morphealike, 
pilar type 
keratinization 
No Inguinal lymph nodes (3 
right, 4 left, 1 Cloquet) 
Radical vulvectomy, bilateral inguinal 
lymphadenectomy, post-operative radiation to 
pelvis and inguinal areas. Patient alive and well at 
1 yr and 2 month follow-up 
 et 
  
5 74 6 x 4, 1 (two lesions) 
 
Infiltrated subcutaneous 
fat, extended to perineal 
body and approaching 
anal skin 
Solid, adenoid, areas 
of keratinization, 
infrequent mitoses 
No Inguinal lymph nodes 
(2/12 left, superficial) 
Radical vulvectomy, bilateral inguinal 
lymphadenectomy 
Winkleman
n et  
6 71 6 x 15 
 
Morpheic Yes 
(bilateral) 
Inguinal lymph node 
(1/6 right, 0/8 left) 
Pre-operative radiation to vulva, symphysis pubis 
and perineal body (complete resolution), radical 
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 Ulceration and necrosis 
to the depth of the 
symphysis pubis 
vulvectomy and proctectomy with removal of the 
anus with transverse colostomy, inguinal 
lymphadenectomy 
Gleeson et 
  
7 86 2.5 x 4 
 
Shallow ulcer 
Nodular, adenoid, few 
mitotic figures, 
hyperkeratotic 
squamous epithelium 
Yes (left) Inguinal lymph node 
(right) 
Radical vulvectomy, bilateral inguinofemoral 
lymphadenectomy. Patient disease free at 1-year 
follow-up 
 
et   
8 79 10 x 8 
 
Infiltrated deep and 
lateral subcutaneous 
tissues 
Adenoid, squamoid 
tumor cells, mitotic 
figures observed, 
vascular invasions, 
tumor embolizations 
Yes 
(bilateral) 
Inguinal lymph nodes 
(10/26) 
 
Skin (right thigh) 
The skin metastasis on the right thigh was slightly 
reduced by radiation before pt was lost to follow-
up. (Pt had undergone radical excision of vulvar 
BCC and bilateral lymph node dissection 6 months 
prior). Pt’s breast CA recurred, and she died the 
following year. 
Feakins et 
  
9 --- Infiltrated subcutaneous 
fat (depth= 1.12) 
Infiltrative, compact 
lobular, low mitotic 
count, focal benign 
squamous change 
--- Inguinal lymph node Radical vulvectomy and inguinal 
lymphadenectomy (complete). Local recurrence at 
23 months, tumor eroded into inguinofemoral 
blood vessels causing hemorrhage and septicemia. 
Patient died from BCC. 
Benedet et 
  
10 80 2 x 1 
Infiltrated subcutaneous 
tissue, perineural 
invasion 
--- 
--- 
Supraclavicular lymph 
node 
Treated supraclavicular nodal met with irradiation, 
with apparently complete resolution. Pt developed 
a local recurrence 2 years after this. Pt died of 
renal failure 2 years later (thought 2/2 pelvic and 
abdominal disease) 
Mulayim et 
  
11 86 13 x 8  
 
Infiltrated to pubic 
bone. (Max thickness= 
6), involved perineal 
body and the lower 
vagina. 
Solid, adenoid, mitoses 
common. 
No Femoral head (left) Radical resection of the vulva bilaterally, mons 
anteriorly, perineum posteriorly. Radiation to the 
femoral head metastasis. At 6 months, she 
progressed with multiple bony(right femur, skull) 
and intraperitoneal metastases and died with 
disease. 
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 et  
 
12 87 5 x 3.7 Infiltrative, high 
mitotic figures 
--- Inguinal lymph node 
(left, vs. local 
recurrence) 
 
Pubic bone 
Surgical excision then palliative treatment. Pt was 
alive and well at 14 mo follow-up 
 
 
Table III: BCC Primary Treatment Preceding Local Recurrence 
 
 
Prim ary  t rea tm ent Case  
num ber
Loca l 
Recurrence  
( n=  23 )
Avg.  size  
( cm )  if 
recurrent
Local or w ide local exc ision 261 21 3.0cm (n=7)
Bilat eral simple vulvect omy 40 0 - -
Radical vulvect omy 23 0 - -
Hemi vulvect omy 9 0 - -
Exc isional biopsy 8 1 1cm (n=1)
Radiat ion t herapy 4 1 3cm (n=1)
Elec t rocaut ery 3 0 - -
Mohs micrographic  surgery 7 0 - -
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